# Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

> **NCT03175432** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- BRAF V600 Wild Type
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Intracranial Melanoma
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Melanoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Refractory Melanoma

## Interventions

- **DRUG:** Atezolizumab
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Cobimetinib
- **PROCEDURE:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT03175432
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-15
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03175432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03175432, "Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03175432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*